Signios Biosciences , a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, announced its rebranding from its previous identity as the US
AI in the Cell and Gene Therapy Market (CGT) through improving manufacturing procedures, accelerating drug discovery, and optimizing treatment customization. With more effective and accurate interventions, personalized medicine could revolutionize the healthcare industry and
Salt AI, founded by the high-performance computing (HPC) team behind MySpace, announces its formal research partnership with the Ellison Medical Institute (EMI), led by cancer
Illumina, Inc., a global leader in next-generation sequencing and array-based technologies, announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine,
Fuel up with free Health Tech Insights
